Cargando…
Could ketamine be the answer to treating treatment-resistant major depressive disorder?
Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7437682/ https://www.ncbi.nlm.nih.gov/pubmed/32875273 http://dx.doi.org/10.1136/gpsych-2020-100227 |